G1043
Guanfacine hydrochloride
≥98% (HPLC)
别名:
N (Aminoiminomethyl)-2,6-dichlorobenzeneacetamide
登录查看公司和协议定价
选择尺寸
关于此项目
经验公式（希尔记法）:
C9H9Cl2N3O · HCl
化学文摘社编号:
分子量:
282.55
MDL编号:
UNSPSC代码:
12352200
PubChem化学物质编号:
NACRES:
NA.77
方案
≥98% (HPLC)
颜色
white
溶解性
H2O: soluble 12 mg/mL at 60 °C
创始人
Promius
SMILES字符串
Cl.NC(=N)NC(=O)Cc1c(Cl)cccc1Cl
InChI
1S/C9H9Cl2N3O.ClH/c10-6-2-1-3-7(11)5(6)4-8(15)14-9(12)13;/h1-3H,4H2,(H4,12,13,14,15);1H
InChI key
DGFYECXYGUIODH-UHFFFAOYSA-N
基因信息
human ... ADRA2A(150), ADRA2B(151), ADRA2C(152)
正在寻找类似产品? 访问 产品对比指南
应用
Guanfacine hydrochloride has been used as an α2A adrenoceptor agonist to test its protective effect on hypobaric hypoxia (HH) and in rat brain to measure blood oxygenation level dependent (BOLD) response.
生化/生理作用
α-2 noradrenergic receptor agonist.
Guanfacine stimulates the brain postsynaptic α2 adrenergic receptor (AR) and mediates the prefrontal cortical (PFC) neuronal regulation and strengthens their network. Guanfacine improves the density of neuronal dendrites and is useful in treating neuropsychiatric disorders. It modulates the synaptic and cytoskeletal proteins expression in prefrontal cortical (PFC) neurons and may improve hypobaric hypoxia (HH) induced PFC dysfunctions. Guanfacine enhances cognitive function and is recommended for attention deficit hyperactivity disorder (ADHD) therapy.
特点和优势
This compound was developed by Promius. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
个人防护装备
Eyeshields, Gloves, type N95 (US)
James Signorovitch et al.
Pharmacoepidemiology and drug safety, 21 Suppl 2, 130-137 (2012-05-11)
To illustrate a matching-adjusted indirect comparison by comparing the efficacy of guanfacine extended release (GXR) and atomoxetine (ATX) in reducing oppositional symptoms in children with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. Individual patient data were used from a GXR
Floyd R Sallee et al.
Journal of child and adolescent psychopharmacology, 22(3), 206-214 (2012-05-23)
Extended-release guanfacine (GXR) is approved for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents aged 6-17 years. This post-hoc analysis further examines the effects of GXR on hyperactivity-impulsivity and inattentiveness. Data from two large double-blind placebo-controlled pivotal trials
Katharine Pillidge et al.
British journal of pharmacology, 171(20), 4785-4796 (2014-07-31)
Mice with functional ablation of substance P-preferring neurokinin-1 receptors (NK1R-/- mice) display behavioural abnormalities resembling those in attention deficit hyperactivity disorder (ADHD). Here, we investigated whether the ADHD treatment, guanfacine, alleviated the hyperactivity and impulsivity/inattention displayed by NK1R-/- mice in
Yuanyuan Li et al.
Rapid communications in mass spectrometry : RCM, 26(10), 1208-1212 (2012-04-14)
A two-layered polymeric membrane is employed for the formation of separated dried plasma spots from whole blood as an alternative to the direct analysis of whole dried blood spots (DBS). This dried plasma spot (DPS) analysis procedure precludes potential issues
Deanne M Buffalari et al.
Psychopharmacology, 223(2), 179-190 (2012-04-25)
Successful treatment of cocaine addiction is severely impeded by the propensity of users to relapse. Withdrawal severity may serve as a key predictor of susceptibility to relapse. Therefore, the identification and treatment of cocaine withdrawal symptoms such as anxiety may
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持